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Enhanced lipid biosynthesis is a characteristic feature of cancer. Deregulated lipogenesis plays an important role in tumour cell
survival. These observations suggest that enzymes in the lipid synthesis pathway would be rational therapeutic targets for cancer.
To this end, we review the enzymes in de novo fatty-acid synthesis and related pathways.
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To establish an effective strategy in molecular cancer therapeutics,
it is essential to identify characteristic features of the disease and to
discover ways to selectively target them. Altered metabolism is
one of the important features of cancer. Initially, Otto Warburg
observed enhanced anaerobic glycolysis in cancer (Warburg,
1956). The elevated glucose catabolism produces an excess of the
glycolytic end-product, pyruvate. Most of the pyruvate is
converted to lactate, whereas some of it is converted to acetyl-
CoA, which, in turn, is used in de novo fatty-acid synthesis
(Figure 1). Highly proliferating cancer cells need to synthesise fatty
acids de novo to continually provide lipids for membrane
production. The synthesised fatty acids are also used for energy
production through b-oxidation and lipid modification of
proteins. De novo fatty-acid synthesis involves two key enzymes,
acetyl-CoA carboxylase (ACC) and fatty-acid synthase (FASN).
ACC carboxylates acetyl-CoA to form malonyl-CoA. The malonyl-
CoA product is further converted by FASN to long-chain fatty
acids. Most normal human tissues preferentially use dietary
(exogenous) lipid for synthesis of new structural lipids, whereas
de novo (endogenous) fatty-acid synthesis is usually suppressed,
and FASN expression is maintained at low levels. By contrast, in
cancer cells, de novo fatty-acid synthesis is commonly elevated and
the supply of cellular fatty acid is highly dependent on the de novo
synthesis. Therefore, deregulated de novo fatty-acid synthesis
directly leads to cellular fatty-acid accumulation and affects
fundamental cellular processes, including signal transduction and
gene expression. Numerous studies have shown overexpression of
FASN in various human epithelial cancers, including prostate,
ovary, colon, lung, endometrium and stomach cancers (Kuhajda,
2000). Moreover, several reports have shown that FASN and
related lipogenic enzymes play important roles in tumour cell
survival at multiple levels.
This minireview summarises recent advances in this field and
provides a theoretical basis for the enzymes in lipogenic pathway
as a new class of molecular targets to induce cancer selective cell
death.
REGULATION OF FASN AND DE NOVO FATTY-ACID
SYNTHESIS PATHWAY IN CANCER
The increased de novo fatty-acid synthesis is caused by multiple
mechanisms, including increased expression of lipogenic enzymes.
Among them, FASN overexpression is observed in a wide variety of
human cancers. In cancer cells, transcriptional regulation of FASN
gene is one of the important mechanisms of FASN overexpression
(Kuhajda, 2006; Menendez and Lupu, 2007). The FASN expression
is regulated by growth factors – growth factor receptors, including
epidermal growth factor receptor (EGFR) and HER2, and steroid
hormone – steroid hormone receptors, such as oestrogen receptor
(ER), androgen receptor (AR) and progesterone receptor (PR).
Downstream of the receptors, the phosphatidylinositol-3-kinase
(PI3K)-Akt and mitogen-activated protein kinase (MAPK) are
candidate signalling pathways that mediate FASN expression
through the sterol regulatory element-binding protein 1c (SREBP-1c).
However, the regulations of FASN expression by the growth factor
receptors are not simple. For instance, mutual regulation between
FASN and the growth factor-dependent signalling is suggested.
HER2 induces FASN expression through the downstream PI3K
signalling (Kumar-Sinha et al, 2003). Conversely, FASN-dependent
regulation of HER2 expression has also been reported (Menendez
et al, 2004). Recent reports have further shown that the FASN
expression is not only controlled by SREBP-1c, but also by other
transcription factors, such as the p53 family proteins and the
lipogenesis-related nuclear protein, SPOT14, which is over-
expressed in breast tumours (D’Erchia et al, 2006; Martel et al, 2006).
As with these intracellular signalling molecules, extracellular
tumour microenvironmental stresses play an important role in
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characterised by a unique pathophysiological microenvironment,
such as hypoxia, low pH, and nutrient starvation. This hostile
microenvironment activates several intracellular signalling path-
ways that promote malignant progression. Hypoxia and low pH
stress induce the FASN expression in cancer cells (Menendez et al,
2005; Furuta et al, 2008). Hypoxia upregulates SREBP-1, the major
transcriptional regulator of the FASN gene, through phosphoryla-
tion of Akt.
Apart from the transcriptional regulation of FASN, it is also
controlled at the posttranslational levels. Graner et al showed that
the isopeptidase USP2a (ubiquitin-specific protease-2a) interacts
with and stabilises FASN protein in prostate cancer (Graner et al,
2004). In breast cancer BT-474 cells that overexpress HER2, the
expression of FASN and ACC are not mediated by SREBP-1, but by
a mammalian target of rapamycin (mTOR)-dependent selective
translational induction (Yoon et al, 2007). A significant copy
number gain of FASN gene is also observed in prostate
adenocarcinoma (Shah et al, 2006). These observations suggest
that tumour-related FASN overexpression could be regulated at
multiple levels (Figure 1).
FASN AND DE NOVO FATTY-ACID SYNTHESIS AS
PROMISING TARGETS OF CANCER
FASN is not only overexpressed in cancer, but it also plays an
essential role in tumour growth and survival. Two well-known
FASN inhibitors, the natural product cerulenin and the synthetic
compound c75, have been studied. Treating tumour cells with
pharmacological inhibitors of FASN effectively suppresses growth
and induces apoptosis in breast cancer cells both in vitro and in
vivo (Pizer et al, 2000). Similarly, FASN knockdown by specific
siRNAs induces apoptosis in prostate cancer LNCaP cells
(De Schrijver et al, 2003). By contrast, the RNAi-mediated
inhibition of FASN did not affect growth rate or viability of
nonmalignant cells. These data indicate that the elevated level of
FASN observed in many cancers actually plays a predominant role
in tumour growth and survival, suggesting that this enzyme could
be a rational therapeutic target.
Although the precise mechanisms of FASN inhibition-induced
cell death in cancer cells still remain unknown, several possibilities
have been proposed. Initial studies indicate that FASN inhibition
accumulates the toxic intermediary metabolite, malonyl-CoA, which
induces apoptosis, whereas pharmacological inhibition of ACC by
5-(tetradecyloxy)-2-furoic acid does not (Pizer et al,2 0 0 0 ) .T h e s e
studies suggest that malonyl-CoA accumulation, but not end-
product fatty-acid depletion, could be a critical factor for apoptosis
induction. However, studies with siRNAs revealed that, as with
FASN inhibition, ACC inhibition triggers apoptosis in prostate and
breast cancer cells, but not in nonmalignant cells (Brusselmans et al,
2005; Chajes et al, 2006). Inhibiting ACC expression results in a
major decrease in the cellular pool of palmitic acid and apoptosis
induction. Moreover, supplementing the culture medium with
palmitic acid completely rescues cells from both ACC and FASN
knockdown-induced apoptosis (Chajes et al, 2006). These observa-
tions re-emphasise the importance of end-product fatty-acid
starvation to cell death. At the same time, these data suggest that,
apart from FASN inhibition, ACC inhibition could also be a rational
strategy to induce selective death of tumour cells. As described
above, FASN and tumour-related survival signals are mutually
regulated, and FASN controls HER2-dependent signalling. Besides
the role of FASN-dependent fatty-acid synthesis in fatty-acid supply
for membrane production and energy production through
b-oxidation, FASN overexpression is further associated with
palmitoylation of signalling proteins (Fiorentino et al,2 0 0 8 ) .
Interference of these pathways could also be involved in the FASN
inhibition-induced selective cancer cytotoxicity.
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Figure 1 Coupling of elevated fatty-acid metabolism with growth factor signalling in cancer. Growth factors and hormone receptors play essential roles in
tumour-related FASN overexpression. FASN and growth factor-dependent signalling are mutually regulated in cancer cells. Tumour microenvironment
stress, as well as multiple other factors are involved in FASN overexpression and elevated lipogenesis in cancer. ACLY, ATP citrate lyase; ACC, acetyl-CoA
carboxylase; FASN, fatty-acid synthase; ACS, acyl-CoA synthetase; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; AR, androgen receptor;
PR, progesterone receptor; PI3K, phosphatidylinositol-3-kinase; MAPK, mitogen-activated protein kinase; SREBP-1c, sterol regulatory element-binding
protein 1c; USP2a, ubiquitin-specific protease-2a.
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and survival, it is involved in other phases of cancer development.
Browne et al showed that Orlistat, an antiobesity drug, inhibits
FASN and suppresses endothelial cell proliferation and angio-
genesis, suggesting a novel role of endothelial cell FASN in
in vivo tumour growth (Browne et al, 2006). FASN overexpression
also confers resistance to Adriamycin and mitoxantrone in
breast cancer cells (Liu et al, 2008). These observations suggest
that FASN inhibition could be a novel strategy to interfere with
tumour survival through angiogenesis and reverse drug resistance
of cancer. Recently, it was reported that FASN inhibition
induces endoplasmic reticulum stress in cancer cells, and FASN
inhibitors cooperate with the endoplasmic reticulum stress inducer
to enhance tumour cell death (Little et al, 2007). Considering
the fact that tumour microenvironment stresses are strong
inducers of the endoplasmic reticulum stress (Murakami et al,
2007), the FASN inhibitors could show selective and enhanced
cytotoxicity to cancer cells under the tumour microenvironment
conditions.
The FASN-dependent de novo fatty-acid synthesis takes place in
cytoplasm. Recently, however, another component of de novo
fatty-acid synthesis in mitochondria was identified (Hiltunen et al,
2009). This suggests that the specificity of FASN inhibitors could
be a critical key for successful molecular target therapy of cancer.
In this aspect, recent determination of the crystal structure of
FASN and molecular description of its active sites (Maier et al,
2008) would help in the development of improved inhibitors.
Cancer cells also induce lipolysis in adipose tissue, a characteristic
feature of cachexia, by producing lipid mobilisation factors
(Tisdale, 2004). However, it is still not clear how the exogenous
lipid mobilised from adipose tissue could affect the dependence of
tumours on de novo fatty-acid synthesis. Polymorphisms of FASN
gene are the other factors that could affect the effectiveness of
FASN-targeting agents on cancer (Kovacs et al, 2004). Further
studies are needed to clarify these points for effective application
of the FASN inhibition strategy to cancer therapy.
OTHER ENZYMES IN LIPOGENIC PATHWAY AS
POTENTIAL CANCER TARGETS
ATP citrate lyase
ATP citrate lyase (ACLY) catalyses the conversion of citrate to
cytosolic acetyl-CoA, thus linking the tumour-associated increase
in glycolysis to enhanced lipogenesis (Figure 1). As with FASN and
ACC, marked elevation of ACLY expression and activity has been
reported in cancer cells (Bauer et al, 2005; Hatzivassiliou et al,
2005). In human lung adenocarcinoma, the expression of
phosphorylated ACLY correlated with stage, differentiation grade,
and a poorer prognosis (Migita et al, 2008). ACLY inhibition by
RNAi leads to a significant impairment of glucose-dependent lipid
synthesis (Bauer et al, 2005). Moreover, ACLY inhibition by
siRNAs or the selective inhibitor SB-204990 suppresses the growth
and survival of tumour cells in vitro and in vivo (Bauer et al, 2005;
Hatzivassiliou et al, 2005; Migita et al, 2008). Although the
molecular mechanisms of ACLY inhibition-dependent cell death
are still not clear, these data suggest that this enzyme could also be
a target for cancer therapy.
Acyl-CoA synthetase
Acyl-CoA synthetase (ACS) is an enzyme that acts downstream of
FASN and converts long-chain fatty acids to acyl-CoA (Figure 1).
This reaction is a critical step in several lipid metabolic pathways,
including phospholipid and triacylglycerol biosynthesis, b-oxida-
tion, and lipid modification of cellular proteins (reviewed in
Coleman et al, 2002). In mammals, five ACS isoforms (ACSL1, 3, 4,
5, and 6) have been identified. All the five members catalyse
saturated and unsaturated fatty acids of chain lengths 8–22
carbons, whereas ACSL4 prefers arachidonic acid (AA) as a
substrate. AA metabolism plays a critical role in colon carcinogenesis.
Cao et al have shown that intracellular-free AA is a mediator of
apoptosis, and ACSL4 suppresses apoptosis by metabolically
lowering the intracellular-free AA level (Cao et al, 2000). They
further showed that ACSL4 is frequently upregulated in colon
adenocarcinoma. These observations strongly suggest that ACSL4
could be involved in tumour cell survival. ACSL5, another ACS
isoform, plays a role in the pathogenesis of cancer. It is frequently
overexpressed in malignant gliomas and is involved in their
growth and survival (Yamashita et al, 2000; Mashima et al, 2009).
Studies with a specific inhibitor of ACS, Triacsin c, further revealed
that ACS inhibition induces selective apoptosis in cancer cells
through the mitochondria-mediated pathway (Mashima et al,
2005). These data indicate that ACS is involved in tumour cell
survival and that ACS inhibition would be an effective strategy for
cancer therapy. At present, it is not clear which ACS member’s
inhibition would best induce selective tumour cell death. Addi-
tional studies are required to clarify the role of each ACS isoform
in normal and cancer cells.
CONCLUSION
Increased de novo fatty-acid synthesis has been recognised as a
hallmark of cancer, whereas its significance in cancer pathogenesis
has long been underestimated. However, the recent advances in
this field have shown the importance of the lipogenic enzymes in
tumour cell survival. From the viewpoint of cancer prevention, it
would also be important to take into account the effects of dietary
factors, such as conjugated linoleic acid, on lipid metabolism in
carcinogenesis (Kelley et al, 2007). Further investigations on the
regulation of these pathways will offer new strategies for tumour
treatment, as well as for effective cancer prevention.
ACKNOWLEDGEMENTS
This work was funded by a Grant-in-Aid for Scientific Research on
Priority Areas, Cancer, from the Ministry of Education, Culture, Sports,
Science and Technology, Japan and by a Grant-in-Aid for Exploratory
Research from Japan Society for the Promotion of Science.
REFERENCES
Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB (2005)
ATP citrate lyase is an important component of cell growth and
transformation. Oncogene 24: 6314–6322
Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell
proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor.
FASEB J 20: 2027–2035
Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV (2005) RNA
interference-mediated silencing of the acetyl-CoA-carboxylase-alpha
gene induces growth inhibition and apoptosis of prostate cancer cells.
Cancer Res 65: 6719–6725
Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM (2000)
Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl
Acad Sci USA 97: 11280–11285
Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006) Acetyl-CoA
carboxylase alpha is essential to breast cancer cell survival. Cancer Res
66: 5287–5294
Cancer therapy targeting lipid metabolism
T Mashima et al
1371
British Journal of Cancer (2009) 100(9), 1369–1372 & 2009 Cancer Research UKColeman RA, Lewin TM, Van Horn CG, Gonzalez-Baro MR (2002) Do long-
chain acyl-CoA synthetases regulate fatty acid entry into synthetic versus
degradative pathways? J Nutr 132: 2123–2126
De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV (2003)
RNA interference-mediated silencing of the fatty acid synthase gene
attenuates growth and induces morphological changes and apoptosis of
LNCaP prostate cancer cells. Cancer Res 63: 3799–3804
D’Erchia AM, Tullo A, Lefkimmiatis K, Saccone C, Sbisa E (2006) The fatty
acid synthase is a conserved p53 family target from worm to human. Cell
Cycle 5: 750–758
Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen
PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler
ME, Mucci L, Giovannucci E, Finn S, Loda M (2008) Overexpression of
fatty acid synthase is associated with palmitoylation of Wnt1 and
cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest
88: 1340–1348
Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S,
Hosobe S, Tsukada T, Miura K, Kamada S, Saito K, Iiizumi M, Liu W,
Ericsson J, Watabe K (2008) Fatty acid synthase gene is up-regulated by
hypoxia via activation of Akt and sterol regulatory element binding
protein-1. Cancer Res 68: 1003–1011
Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer
M, Huesken D, Zimmermann J, Signoretti S, Loda M (2004) The
isopeptidase USP2a regulates the stability of fatty acid synthase in
prostate cancer. Cancer Cell 5: 253–261
Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D,
Hingorani SR, Tuveson DA, Thompson CB (2005) ATP citrate lyase
inhibition can suppress tumor cell growth. Cancer Cell 8: 311–321
Hiltunen JK, Schonauer M, Autio KJ, Mittelmeier TM, Kastaniotis AJ,
Dieckmann CL (2009) Mitochondrial FAS type II – more than just fatty
acids. J Biol Chem (in press)
Kelley NS, Hubbard NE, Erickson KL (2007) Conjugated linoleic acid
isomers and cancer. J Nutr 137: 2599–2607
Kovacs P, Harper I, Hanson RL, Infante AM, Bogardus C, Tataranni PA,
Baier LJ (2004) A novel missense substitution(Val1483Ile) in the fatty
acid synthase gene(FAS) is associated with percentage of body fat and
substrate oxidation rates in nondiabetic Pima Indians. Diabetes 53:
1915–1919
Kuhajda FP (2000) Fatty acid synthase and human cancer: new perspectives
on its role in tumor biology. Nutrition 16: 202–208
Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an
old pathway. Cancer Res 66: 5977–5980
Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM
(2003) Transcriptome analysis of HER2 reveals a molecular connection
to fatty acid synthesis. Cancer Res 63: 132–139
Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ (2007) Inhibition of
fatty acid synthase induces endoplasmic reticulum stress in tumor cells.
Cancer Res 67: 1262–1269
Liu H, Liu Y, Zhang JT (2008) A new mechanism of drug resistance in
breast cancer cells: fatty acid synthase overexpression-mediated
palmitate overproduction. Mol Cancer Ther 7: 263–270
Maier T, Leibundgut M, Ban N (2008) The crystal structure of a mammalian
fatty acid synthase. Science 321: 1315–1322
Martel PM, Binqham CM, Mcgraw CJ, Baker CL, Morganelli PM, Meng ML,
Armstrong JM, Moncur JT, Kinlaw WB (2006) S14 protein in
breast cancer cells: direct evidence of regulation by SREBP-1c,
superinduction with progestin, and effects on cell growth. Exp Cell Res
312: 278–288
Mashima T, Oh-hara T, Sato S, Mochizuki M, Sugimoto Y, Yamazaki K,
Hamada J, Tada M, Moriuchi T, Ishikawa Y, Kato Y, Tomoda H, Yamori
T, Tsuruo T (2005) p53-defective tumors with a functional apoptosome-
mediated pathway: a new therapeutic target. J Natl Cancer Inst 97:
765–777
Mashima T, Sato S, Sugimoto Y, Tsuruo T, Seimiya H (2009) Promotion of
glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis
conditions. Oncogene 28: 9–19
Menendez JA, Decker JP, Lupu R (2005) In support of fatty acid synthase
(FAS) as a metabolic oncogene: extracellular acidosis acts in an
epigenetic fashion activating FAS gene expression in cancer cells. J Cell
Biochem 94: 1–4
Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic
phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763–777
Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R
(2004) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu
(erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci
USA 101: 10715–10720
Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima
M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y
(2008) ATP citrate lyase: activation and therapeutic implications in
non-small cell lung cancer. Cancer Res 68: 8547–8554
Murakami S, Noguchi T, Takeda K, Ichijo H (2007) Stress signalling in
cancer. Cancer Sci 98: 1521–1527
Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend
CA, Kuhajda FP (2000) Malonyl-coenzyme-A is a potential mediator of
cytotoxicity induced by fatty-acid synthase inhibition in human breast
cancer cells and xenografts. Cancer Res 60: 213–218
Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, Acquafondata M, Pflug
BR (2006) Fatty acid synthase gene overexpression and copy number
gain in prostate adenocarcinoma. Hum Pathol 37: 401–409
Tisdale MJ (2004) Tumor-host interactions. J Cell Biochem 93:
871–877
Warburg O (1956) On the origin of cancer cells. Science 123: 309–314
Yamashita Y, Kumabe T, Cho YY, Watanabe M, Kawagishi J, Yoshimoto T,
Fujino T, Kang MJ, Yamamoto TT (2000) Fatty acid induced glioma cell
growth is mediated by the acyl-CoA synthetase 5 gene located on
chromosome 10q25.1-q25.2, a region frequently deleted in malignant
gliomas. Oncogene 19: 5919–5925
Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, Kim KS
(2007) Up-regulation of acetyl-CoA carboxylase alpha and fatty
acid synthase by human epidermal growth factor receptor 2 at
the translational level in breast cancer cells. J Biol Chem 282:
26122–26131
Cancer therapy targeting lipid metabolism
T Mashima et al
1372
British Journal of Cancer (2009) 100(9), 1369–1372 & 2009 Cancer Research UK